Cheng Fang

Pamiparib plus surufatinib with ctDNA monitoring in platinum-resistant ovarian cancer after PARP inhibitor progression: a phase Ib/II trial (POST-PARPi)

<title>Abstract</title> Background PARP inhibitors (PARPi) are standard front-line maintenance therapy for advanced ovarian cancer, but the efficacy of PARPi retreatment in later lines remains unclear. This phase Ib/II study evaluated the combination of pamiparib (a PARPi) and su...